120 related articles for article (PubMed ID: 34803924)
1. Oral Antidiabetics and Sleep Among Type 2 Diabetes Patients: Data From the UK Biobank.
Xue P; Wu J; Tang X; Tan X; Benedict C
Front Endocrinol (Lausanne); 2021; 12():763138. PubMed ID: 34803924
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Association of poor sleep and HbA1c in metformin-treated patients with type 2 diabetes: Findings from the UK Biobank cohort study.
Xue P; Tan X; Benedict C
J Sleep Res; 2023 Oct; 32(5):e13917. PubMed ID: 37106473
[TBL] [Abstract][Full Text] [Related]
4. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
5. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
6. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Metformin Dosage Uptitration Versus Adding Another Antihyperglycemic Medication on Glycemic Control in Type 2 Diabetes Patients Failing Initial Metformin Monotherapy: A Retrospective Cohort Study.
Mahabaleshwarkar R; Liu TL; Mulder H
Popul Health Manag; 2019 Oct; 22(5):457-463. PubMed ID: 30628868
[TBL] [Abstract][Full Text] [Related]
8. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
9. Baseline Vitamin D Status, Sleep Patterns, and the Risk of Incident Type 2 Diabetes in Data From the UK Biobank Study.
Wang M; Zhou T; Li X; Ma H; Liang Z; Fonseca VA; Heianza Y; Qi L
Diabetes Care; 2020 Nov; 43(11):2776-2784. PubMed ID: 32847829
[TBL] [Abstract][Full Text] [Related]
10. Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus.
Jermendy G; Wittmann I; Nagy L; Kiss Z; Rokszin G; Abonyi-Tóth Z; Katona L; Paragh G; Karádi I; Merkely B
Med Sci Monit; 2012 Feb; 18(2):CR72-77. PubMed ID: 22293880
[TBL] [Abstract][Full Text] [Related]
11. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
12. Association of Self-Reported Sleep and Circadian Measures With Glycemia in Adults With Prediabetes or Recently Diagnosed Untreated Type 2 Diabetes.
Mokhlesi B; Temple KA; Tjaden AH; Edelstein SL; Utzschneider KM; Nadeau KJ; Hannon TS; Sam S; Barengolts E; Manchanda S; Ehrmann DA; Van Cauter E;
Diabetes Care; 2019 Jul; 42(7):1326-1332. PubMed ID: 31048411
[TBL] [Abstract][Full Text] [Related]
13. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
[TBL] [Abstract][Full Text] [Related]
14. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.
Morgan CL; Poole CD; Evans M; Barnett AH; Jenkins-Jones S; Currie CJ
J Clin Endocrinol Metab; 2012 Dec; 97(12):4605-12. PubMed ID: 23076348
[TBL] [Abstract][Full Text] [Related]
15. Metformin and the risk of head and neck cancer: a case-control analysis.
Becker C; Jick SS; Meier CR; Bodmer M
Diabetes Obes Metab; 2014 Nov; 16(11):1148-54. PubMed ID: 25041125
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
17. Progression through diabetes therapies among new elderly users of metformin: a population-based study.
Gomes T; Juurlink DN; Shah BR; Hellings CR; Paterson JM; Mamdani MM
Diabet Med; 2013 Feb; 30(2):e51-5. PubMed ID: 23075391
[TBL] [Abstract][Full Text] [Related]
18. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
Ong CR; Molyneaux LM; Constantino MI; Twigg SM; Yue DK
Diabetes Care; 2006 Nov; 29(11):2361-4. PubMed ID: 17065668
[TBL] [Abstract][Full Text] [Related]
20. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
